Galera Therapeutics raises $150 million in largest-ever Series C raise by a St. Louis bioscience company
Clinical-stage drug discovery company Galera Therapeutics has raised $150 million in a Series C financing and royalty purchase agreement. According to a release, it is the largest ever Series C raise by a St. Louis bioscience company.
Led by Clarus, proceeds from the raise will be used for the clinical development of the drug GC4419, which has shown to reduce the incidence and duration of severe oral mucositis, a side effect of radiation treatment in head and neck cancer patients that causes painful…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Vince Brennan Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Head and Neck Cancer | Health Management | Oral Cancer